Discovery of AG-120: A first-in-class inhibitor of IDH1 mutant enzymes for the treatment of cancers harboring IDH1 mutations

被引：0
|
作者：
Popovici-Muller, Janeta [1 ]
Lemieux, Rene [2 ]
Saunders, Jeffrey [3 ]
Salituro, Francesco [4 ]
Yen, Katharine [1 ]
Straley, Kimberly [5 ]
Tobin, Erica [1 ]
Wang, Fang [1 ]
Gross, Stefan [1 ]
Artin, Erin [1 ]
Dang, Lenny [1 ]
Yang, Hua [1 ]
Utley, Luke [6 ]
Chen, Yue [1 ]
Olaharski, Andrew [1 ]
Silverman, Lee [1 ]
Agresta, Sam [1 ]
Su, Michael [1 ]
Biller, Scott [1 ]
机构：
[1] Agios Pharmaceut, Cambridge, MA USA
[2] KSQ Therapeut, Cambridge, MA USA
[3] Resilience Therapeut, Boston, MA USA
[4] Sage Therapeut, Cambridge, MA USA
[5] Vertex Pharmaceut, Boston, MA USA
[6] Alnylam Pharmaceut, Cambridge, MA USA
来源：
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY | 2016年 / 252卷
关键词：
D O I：
暂无
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
268
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Metabolic addiction in IDH1 mutant cancers
    Chi, Andrew S.
    Tateishi, Kensuke
    Hiroaki, VVakimoto
    Batchelor, Tracy T.
    Lafrate, Anthony J.
    Cahill, Daniel P.
    CANCER RESEARCH, 2016, 76
  • [22] Functional characterization of the ivosidenib (AG-120) and azacitidine combination in a mutant IDH1 AML cell model
    Yen, Katharine
    Chopra, Vivek S.
    Tobin, Erica
    Avanzino, Brian
    Mavrommatis, Konstantinos
    DiMartino, Jorge
    MacBeth, Kyle J.
    CANCER RESEARCH, 2018, 78 (13)
  • [23] Vorasidenib (AG-881): A First-in-Class, Brain-Penetrant Dual Inhibitor of Mutant IDH1 and 2 for Treatment of Glioma
    Konteatis, Zenon
    Artin, Erin
    Nicolay, Brandon
    Straley, Kimberly
    Padyana, Anil K.
    Jin, Lei
    Chen, Yue
    Narayaraswamy, Rohini
    Tong, Shuilong
    Wang, Feng
    Zhou, Ding
    Cui, Dawei
    Cai, Zhenwei
    Luo, Zhiyong
    Fang, Cheng
    Tang, Huachun
    Lv, Xiaobing
    Nagaraja, Raj
    Yang, Hua
    Su, Shin-San M.
    Sui, Zhihua
    Dang, Lenny
    Yen, Katharine
    Popovici-Muller, Janeta
    Codega, Paolo
    Campos, Carl
    Mellinghoff, Ingo K.
    Biller, Scott A.
    ACS MEDICINAL CHEMISTRY LETTERS, 2020, 11 (02): : 101 - 107
  • [24] Discovery of Aloperine as a Potential Antineoplastic Agent for Cholangiocarcinoma Harboring Mutant IDH1
    Wu, Xingkang
    Li, Yang
    Han, Chenchen
    Li, Shifei
    Qin, Xuemei
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (17)
  • [25] Ivosidenib (AG-120) in Mutant IDH1 Relapsed/Refractory Acute Myeloid Leukemia: Results of a Phase 1 Study
    DiNardo, Courtney D.
    Stein, Eytan M.
    de Botton, Stephane
    Roboz, Gail J.
    Altman, Jessica K.
    Mims, Alice S.
    Swords, Ronan
    Collins, Robert H.
    Mannis, Gabriel N.
    Pollyea, Daniel A.
    Donnellan, Will
    Fathi, Amir T.
    Pigneux, Arnaud
    Erba, Harry P.
    Prince, Gabrielle T.
    Stein, Anthony S.
    Uy, Geoffrey L.
    Foran, James M.
    Traer, Elie
    Stuart, Robert K.
    Arellano, Martha L.
    Slack, James L.
    Sekeres, Mikkael A.
    Willekens, Christophe
    Choe, Sung
    Wang, Hongfang
    Zhang, Vickie
    Yen, Katharine E.
    Kapsalis, Stephanie M.
    Yang, Hua
    Dai, David
    Fan, Bin
    Goldwasser, Meredith
    Liu, Hua
    Agresta, Sam
    Wu, Bin
    Attar, Eyal C.
    Tallman, Martin S.
    Stone, Richard M.
    Kantarjian, Hagop M.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S204 - S205
  • [26] AG-120, an Oral, Selective, First-in-Class, Potent Inhibitor of Mutant IDH1, Reduces Intracellular 2HG and Induces Cellular Differentiation in TF-1 R132H Cells and Primary Human IDH1 Mutant AML Patient Samples Treated Ex Vivo
    Hansen, Erica
    Quivoron, Cyril
    Straley, Kim
    Lemieux, Rene M.
    Popovici-Muller, Janeta
    Sadrzadeh, Hossein
    Fathi, Amir T.
    Gliser, Camelia
    David, Muriel
    Saada, Veronique
    Micol, Jean-Baptiste
    Bernard, Olivier
    Dorsch, Marion
    Yang, Hua
    Su, Michael
    Agresta, Sam
    de Botton, Stephane
    Penard-Lacronique, Virginie
    Yen, Katharine
    BLOOD, 2014, 124 (21)
  • [27] Discovery and evaluation of clinical candidate IDH305: A brain penetrant mutant IDH1 inhibitor
    Cho, Young Shin
    Levell, Julian
    Liu, Gang
    Caferro, Thomas
    Shafer, Cynthia
    Costales, Abran
    Manning, James
    Zhao, Qian
    Sendzik, Martin
    Shultz, Michael
    Dooley, Julia
    Chenail, Gregg
    Farsidjani, Ali
    Chen, Jinyun
    Kulathila, Ragiraj
    Xie, Xiaoling
    Dodd, Stephanie
    Gould, Ty
    Liang, Guiqing
    Heimbach, Tycho
    Slocum, Kelly
    Pu, Minying
    Pagliarini, Raymond
    Growney, Joseph
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2017, 254
  • [28] IDH-mutant glioma: A new IDH1 inhibitor moves forward
    Miller, Julie J.
    Arrillaga-Romany, Isabel
    NEURO-ONCOLOGY, 2023, 25 (02) : 337 - 338
  • [29] Discovery and Evaluation of Clinical Candidate IDH305, a Brain Penetrant Mutant IDH1 Inhibitor
    Cho, Young Shin
    Levell, Julian R.
    Liu, Gang
    Caferro, Thomas
    Sutton, James
    Shafer, Cynthia M.
    Costales, Abran
    Manning, James R.
    Zhao, Qian
    Sendzik, Martin
    Shultz, Michael
    Chenail, Gregg
    Dooley, Julia
    Villalba, Brian
    Farsidjani, Ali
    Chen, Jinyun
    Kulathila, Raviraj
    Xie, Xiaoling
    Dodd, Stephanie
    Gould, Ty
    Liang, Guiqing
    Heimbach, Tycho
    Slocum, Kelly
    Firestone, Brant
    Pu, Minying
    Pagliarini, Raymond
    Growney, Joseph D.
    ACS MEDICINAL CHEMISTRY LETTERS, 2017, 8 (10): : 1116 - 1121
  • [30] Synergistic activity of IDH1 inhibitor BAY1436032 with azacitidine in IDH1 mutant acute myeloid leukemia
    Chaturvedi, Anuhar
    Gupta, Charu
    Gabdoulline, Razif
    Borchert, Nora M.
    Goparaju, Ramya
    Kaulfuss, Stefan
    Goerlich, Kerstin
    Schottmann, Renate
    Othman, Basem
    Welzenbach, Julia
    Panknin, Olaf
    Wagner, Markus
    Geffers, Robert
    Ganser, Arnold
    Thol, Felicitas
    Haegebarth, Andrea
    Jeffers, Michael
    Heuser, Michael
    HAEMATOLOGICA, 2021, 106 (02) : 565 - 573
12345